Compass Pathways PLC
Change company Symbol lookup
Select an option...
CMPS Compass Pathways PLC
OGN Organon & Co
BBWI Bath & Body Works Inc
OPI Office Properties Income Trust
DHC Diversified Healthcare Trust
GNL-A Global Net Lease Inc
PRS Prudential Financial Inc
LEN Lennar Corp
LEG Leggett & Platt Inc
LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc
Go

Health Care : Biotechnology |
Based in United Kingdom

COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for anorexia nervosa and post-traumatic stress disorder (PTSD). The Company is also developing its investigational COMP360 psilocybin therapy for the treatment of a range of mental health conditions, with an initial focus on TRD.

Closing Price: $7.88

Day's Change: 0.29 (3.82%)

Bid: --

Ask: --

B/A Size: --

Day's High: 7.97

Day's Low: 7.60

Volume (Average) Volume: 173,863 10-day average volume: 177,270: 173,863

May 31, 2023
8:30 am ET	COMPASS Pathways' Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer(Globe Newswire)
8:30 am ET	COMPASS Pathways' Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer She will remain a member of the COMPASS Pathways Board of Directors LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based...(Thomson Reuters ONE)
May 26, 2023
4:00 pm ET	COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference(Globe Newswire)
10:28 am ET	Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients By Barbara Kollmeyer Ingredient found in magic mushrooms showed remission in patients after 18 months Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a...(MarketWatch)
7:00 am ET	Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023(Globe Newswire)
May 11, 2023
7:00 am ET	COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights(Globe Newswire)
7:00 am ET	COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights LONDON, May 11, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the...(Thomson Reuters ONE)
May 03, 2023
4:01 pm ET	COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023(Globe Newswire)
May 02, 2023
7:00 am ET	American Medical Association to Issue First New Code for Psychedelic Therapies(Globe Newswire)
7:00 am ET	American Medical Association to Issue First New Code for Psychedelic Therapies COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved LONDON and SAN JOSE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS)...(Thomson Reuters ONE)
April 10, 2023
10:10 am ET	COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference(Globe Newswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and